These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33275608)

  • 21. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.
    Wichgers Schreur PJ; Kant J; van Keulen L; Moormann RJ; Kortekaas J
    Vaccine; 2015 Mar; 33(12):1459-64. PubMed ID: 25665959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.
    Jyothi SJ; Patil SR; Reddy NY; Panduranga RP; Madala U; Prakash GM; Putty K
    Onderstepoort J Vet Res; 2020 Oct; 87(1):e1-e6. PubMed ID: 33054261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination.
    Wilson WC; Bawa B; Drolet BS; Lehiy C; Faburay B; Jasperson DC; Reister L; Gaudreault NN; Carlson J; Ma W; Morozov I; McVey DS; Richt JA
    Vet Microbiol; 2014 Aug; 172(1-2):44-50. PubMed ID: 24856133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.
    Bouet-Cararo C; Contreras V; Caruso A; Top S; Szelechowski M; Bergeron C; Viarouge C; Desprat A; Relmy A; Guibert JM; Dubois E; Thiery R; Bréard E; Bertagnoli S; Richardson J; Foucras G; Meyer G; Schwartz-Cornil I; Zientara S; Klonjkowski B
    PLoS One; 2014; 9(11):e111605. PubMed ID: 25364822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.
    Miller MM; Bennett KE; Drolet BS; Lindsay R; Mecham JO; Reeves WK; Weingartl HM; Wilson WC
    Clin Vaccine Immunol; 2015 Aug; 22(8):930-7. PubMed ID: 26041042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A protective bivalent vaccine against Rift Valley fever and bluetongue.
    Calvo-Pinilla E; Marín-López A; Moreno S; Lorenzo G; Utrilla-Trigo S; Jiménez-Cabello L; Benavides J; Nogales A; Blasco R; Brun A; Ortego J
    NPJ Vaccines; 2020; 5(1):70. PubMed ID: 32793399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
    Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
    PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rift Valley Fever Phlebovirus Reassortment Study in Sheep.
    Balaraman V; Indran SV; Kim IJ; Trujillo JD; Meekins DA; Shivanna V; Zajac MD; Urbaniak K; Morozov I; Sunwoo SY; Faburay B; Osterrieder K; Gaudreault NN; Wilson WC; Richt JA
    Viruses; 2024 May; 16(6):. PubMed ID: 38932172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
    Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
    Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.
    Matsuo E; Celma CC; Boyce M; Viarouge C; Sailleau C; Dubois E; Bréard E; Thiéry R; Zientara S; Roy P
    J Virol; 2011 Oct; 85(19):10213-21. PubMed ID: 21795358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
    Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
    J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.
    Morrill JC; Mebus CA; Peters CJ
    Am J Vet Res; 1997 Oct; 58(10):1104-9. PubMed ID: 9328662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.
    van Rijn PA; Maris-Veldhuis MA; van Gennip RGP
    Viruses; 2021 May; 13(5):. PubMed ID: 34067226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.
    Soi RK; Rurangirwa FR; McGuire TC; Rwambo PM; DeMartini JC; Crawford TB
    Clin Vaccine Immunol; 2010 Dec; 17(12):1842-9. PubMed ID: 20876822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.
    Bird BH; Maartens LH; Campbell S; Erasmus BJ; Erickson BR; Dodd KA; Spiropoulou CF; Cannon D; Drew CP; Knust B; McElroy AK; Khristova ML; Albariño CG; Nichol ST
    J Virol; 2011 Dec; 85(24):12901-9. PubMed ID: 21976656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
    Morrill JC; Mebus CA; Peters CJ
    Am J Vet Res; 1997 Oct; 58(10):1110-4. PubMed ID: 9328663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
    López-Gil E; Lorenzo G; Hevia E; Borrego B; Eiden M; Groschup M; Gilbert SC; Brun A
    PLoS Negl Trop Dis; 2013; 7(7):e2309. PubMed ID: 23875044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge.
    Boshra H; Lorenzo G; Rodriguez F; Brun A
    Vaccine; 2011 Jun; 29(27):4469-75. PubMed ID: 21549790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.